|
Gene: ELOVL5 |
Gene summary for ELOVL5 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ELOVL5 | Gene ID | 60481 |
Gene name | ELOVL fatty acid elongase 5 | |
Gene Alias | HELO1 | |
Cytomap | 6p12.1 | |
Gene Type | protein-coding | GO ID | GO:0000038 | UniProtAcc | Q9NYP7 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
60481 | ELOVL5 | P104T-E | Human | Esophagus | ESCC | 2.60e-02 | -1.85e-01 | 0.0931 |
60481 | ELOVL5 | P107T-E | Human | Esophagus | ESCC | 5.49e-49 | 1.44e+00 | 0.171 |
60481 | ELOVL5 | P127T-E | Human | Esophagus | ESCC | 3.22e-02 | 2.19e-01 | 0.0826 |
60481 | ELOVL5 | P128T-E | Human | Esophagus | ESCC | 1.40e-18 | 1.07e+00 | 0.1241 |
60481 | ELOVL5 | P130T-E | Human | Esophagus | ESCC | 1.25e-62 | 1.82e+00 | 0.1676 |
60481 | ELOVL5 | S43 | Human | Liver | Cirrhotic | 1.12e-03 | -1.04e-01 | -0.0187 |
60481 | ELOVL5 | HCC1_Meng | Human | Liver | HCC | 9.11e-71 | -1.79e-02 | 0.0246 |
60481 | ELOVL5 | HCC2_Meng | Human | Liver | HCC | 9.03e-09 | -1.86e-01 | 0.0107 |
60481 | ELOVL5 | cirrhotic2 | Human | Liver | Cirrhotic | 3.34e-03 | 4.78e-04 | 0.0201 |
60481 | ELOVL5 | cirrhotic3 | Human | Liver | Cirrhotic | 1.73e-02 | -8.83e-02 | 0.0215 |
60481 | ELOVL5 | HCC1 | Human | Liver | HCC | 7.45e-04 | 4.19e+00 | 0.5336 |
60481 | ELOVL5 | HCC2 | Human | Liver | HCC | 3.98e-04 | 2.99e+00 | 0.5341 |
60481 | ELOVL5 | Pt13.a | Human | Liver | HCC | 1.86e-03 | 2.29e-01 | 0.021 |
60481 | ELOVL5 | Pt13.b | Human | Liver | HCC | 5.48e-30 | 3.69e-01 | 0.0251 |
60481 | ELOVL5 | Pt14.a | Human | Liver | HCC | 2.54e-04 | 1.58e-01 | 0.0169 |
60481 | ELOVL5 | Pt14.b | Human | Liver | HCC | 1.03e-03 | 1.71e-01 | 0.018 |
60481 | ELOVL5 | S014 | Human | Liver | HCC | 3.14e-16 | 8.05e-01 | 0.2254 |
60481 | ELOVL5 | S015 | Human | Liver | HCC | 3.11e-22 | 1.16e+00 | 0.2375 |
60481 | ELOVL5 | S016 | Human | Liver | HCC | 3.97e-22 | 9.88e-01 | 0.2243 |
60481 | ELOVL5 | S027 | Human | Liver | HCC | 3.82e-09 | 1.22e+00 | 0.2446 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00196938 | Breast | Precancer | ribose phosphate metabolic process | 49/1080 | 396/18723 | 3.81e-07 | 1.78e-05 | 49 |
GO:00091528 | Breast | Precancer | purine ribonucleotide biosynthetic process | 28/1080 | 169/18723 | 4.17e-07 | 1.89e-05 | 28 |
GO:00463907 | Breast | Precancer | ribose phosphate biosynthetic process | 30/1080 | 190/18723 | 4.75e-07 | 2.11e-05 | 30 |
GO:00092607 | Breast | Precancer | ribonucleotide biosynthetic process | 29/1080 | 182/18723 | 6.05e-07 | 2.55e-05 | 29 |
GO:00091509 | Breast | Precancer | purine ribonucleotide metabolic process | 46/1080 | 368/18723 | 6.47e-07 | 2.71e-05 | 46 |
GO:00091179 | Breast | Precancer | nucleotide metabolic process | 56/1080 | 489/18723 | 7.40e-07 | 3.00e-05 | 56 |
GO:00092598 | Breast | Precancer | ribonucleotide metabolic process | 47/1080 | 385/18723 | 9.69e-07 | 3.84e-05 | 47 |
GO:00067539 | Breast | Precancer | nucleoside phosphate metabolic process | 56/1080 | 497/18723 | 1.24e-06 | 4.70e-05 | 56 |
GO:00061639 | Breast | Precancer | purine nucleotide metabolic process | 47/1080 | 396/18723 | 2.14e-06 | 7.50e-05 | 47 |
GO:00061647 | Breast | Precancer | purine nucleotide biosynthetic process | 28/1080 | 191/18723 | 5.04e-06 | 1.52e-04 | 28 |
GO:00725219 | Breast | Precancer | purine-containing compound metabolic process | 47/1080 | 416/18723 | 8.19e-06 | 2.20e-04 | 47 |
GO:00725227 | Breast | Precancer | purine-containing compound biosynthetic process | 28/1080 | 200/18723 | 1.23e-05 | 3.17e-04 | 28 |
GO:00091655 | Breast | Precancer | nucleotide biosynthetic process | 32/1080 | 254/18723 | 2.72e-05 | 6.21e-04 | 32 |
GO:19012935 | Breast | Precancer | nucleoside phosphate biosynthetic process | 32/1080 | 256/18723 | 3.18e-05 | 6.97e-04 | 32 |
GO:00192164 | Breast | Precancer | regulation of lipid metabolic process | 34/1080 | 331/18723 | 8.14e-04 | 9.55e-03 | 34 |
GO:00463946 | Breast | Precancer | carboxylic acid biosynthetic process | 32/1080 | 314/18723 | 1.30e-03 | 1.38e-02 | 32 |
GO:00723304 | Breast | Precancer | monocarboxylic acid biosynthetic process | 24/1080 | 214/18723 | 1.41e-03 | 1.48e-02 | 24 |
GO:00160536 | Breast | Precancer | organic acid biosynthetic process | 32/1080 | 316/18723 | 1.44e-03 | 1.50e-02 | 32 |
GO:00066335 | Breast | Precancer | fatty acid biosynthetic process | 19/1080 | 163/18723 | 2.74e-03 | 2.42e-02 | 19 |
GO:00620126 | Breast | Precancer | regulation of small molecule metabolic process | 32/1080 | 334/18723 | 3.45e-03 | 2.87e-02 | 32 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa012129 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa0121214 | Esophagus | ESCC | Fatty acid metabolism | 41/4205 | 57/8465 | 5.13e-04 | 1.75e-03 | 8.98e-04 | 41 |
hsa012122 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa01040 | Liver | Cirrhotic | Biosynthesis of unsaturated fatty acids | 14/2530 | 27/8465 | 1.36e-02 | 4.25e-02 | 2.62e-02 | 14 |
hsa012123 | Liver | Cirrhotic | Fatty acid metabolism | 32/2530 | 57/8465 | 3.12e-05 | 2.47e-04 | 1.52e-04 | 32 |
hsa010401 | Liver | Cirrhotic | Biosynthesis of unsaturated fatty acids | 14/2530 | 27/8465 | 1.36e-02 | 4.25e-02 | 2.62e-02 | 14 |
hsa012124 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa000622 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
hsa010402 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
hsa012125 | Liver | HCC | Fatty acid metabolism | 45/4020 | 57/8465 | 1.05e-06 | 1.10e-05 | 6.09e-06 | 45 |
hsa0006211 | Liver | HCC | Fatty acid elongation | 20/4020 | 27/8465 | 4.58e-03 | 1.36e-02 | 7.55e-03 | 20 |
hsa010403 | Liver | HCC | Biosynthesis of unsaturated fatty acids | 19/4020 | 27/8465 | 1.37e-02 | 3.33e-02 | 1.85e-02 | 19 |
hsa012128 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
hsa0121213 | Oral cavity | OSCC | Fatty acid metabolism | 35/3704 | 57/8465 | 5.37e-03 | 1.29e-02 | 6.55e-03 | 35 |
hsa012127 | Prostate | BPH | Fatty acid metabolism | 19/1718 | 57/8465 | 1.44e-02 | 4.17e-02 | 2.58e-02 | 19 |
hsa0121212 | Prostate | BPH | Fatty acid metabolism | 19/1718 | 57/8465 | 1.44e-02 | 4.17e-02 | 2.58e-02 | 19 |
hsa0121221 | Prostate | Tumor | Fatty acid metabolism | 23/1791 | 57/8465 | 7.60e-04 | 3.59e-03 | 2.23e-03 | 23 |
hsa010404 | Prostate | Tumor | Biosynthesis of unsaturated fatty acids | 12/1791 | 27/8465 | 5.53e-03 | 1.93e-02 | 1.19e-02 | 12 |
hsa0121231 | Prostate | Tumor | Fatty acid metabolism | 23/1791 | 57/8465 | 7.60e-04 | 3.59e-03 | 2.23e-03 | 23 |
hsa0104011 | Prostate | Tumor | Biosynthesis of unsaturated fatty acids | 12/1791 | 27/8465 | 5.53e-03 | 1.93e-02 | 1.19e-02 | 12 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ELOVL5 | SNV | Missense_Mutation | c.896N>C | p.Gly299Ala | p.G299A | Q9NYP7 | protein_coding | tolerated(0.08) | possibly_damaging(0.523) | TCGA-A8-A085-01 | Breast | breast invasive carcinoma | Male | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ELOVL5 | SNV | Missense_Mutation | c.208N>T | p.Leu70Phe | p.L70F | Q9NYP7 | protein_coding | tolerated(0.61) | benign(0.053) | TCGA-AR-A1AW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD | |
ELOVL5 | SNV | Missense_Mutation | c.67N>A | p.Val23Ile | p.V23I | Q9NYP7 | protein_coding | deleterious(0.03) | possibly_damaging(0.794) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
ELOVL5 | SNV | Missense_Mutation | novel | c.905N>A | p.Ala302Asp | p.A302D | Q9NYP7 | protein_coding | deleterious(0.02) | benign(0.006) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
ELOVL5 | SNV | Missense_Mutation | c.826N>G | p.Phe276Val | p.F276V | Q9NYP7 | protein_coding | deleterious(0) | probably_damaging(0.977) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ELOVL5 | SNV | Missense_Mutation | rs766390073 | c.380N>A | p.Arg127His | p.R127H | Q9NYP7 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ELOVL5 | SNV | Missense_Mutation | novel | c.482N>C | p.Lys161Thr | p.K161T | Q9NYP7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ELOVL5 | SNV | Missense_Mutation | c.356N>G | p.Tyr119Cys | p.Y119C | Q9NYP7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ELOVL5 | SNV | Missense_Mutation | rs780696778 | c.947A>G | p.Asn316Ser | p.N316S | Q9NYP7 | protein_coding | tolerated(0.07) | benign(0.006) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ELOVL5 | insertion | Frame_Shift_Ins | novel | c.59_60insACATA | p.Asp20GlufsTer6 | p.D20Efs*6 | Q9NYP7 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |